Wells Fargo & Company Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine (NASDAQ:IRON) had its target price increased by equities research analysts at Wells Fargo & Company from $78.00 to $79.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 19.65% from the stock’s previous close.

IRON has been the subject of a number of other reports. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wedbush decreased their price objective on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. Cantor Fitzgerald lowered their target price on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Finally, BMO Capital Markets dropped their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus price target of $102.09.

Disc Medicine Trading Down 0.9%

NASDAQ:IRON traded down $0.60 during trading hours on Monday, hitting $66.03. The stock had a trading volume of 79,199 shares, compared to its average volume of 744,816. The business’s 50 day moving average is $74.43 and its 200-day moving average is $75.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -11.05 and a beta of 0.87. Disc Medicine has a one year low of $30.82 and a one year high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. Sell-side analysts anticipate that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,414,806.64. This trade represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jean M. Franchi sold 7,081 shares of Disc Medicine stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total value of $463,593.07. Following the transaction, the chief financial officer owned 71,343 shares of the company’s stock, valued at $4,670,826.21. This represents a 9.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 285,114 shares of company stock worth $24,937,862 in the last three months. Insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine in the 4th quarter valued at approximately $33,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine during the 3rd quarter worth approximately $38,000. KBC Group NV bought a new position in Disc Medicine in the fourth quarter valued at approximately $80,000. CWM LLC raised its position in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares in the last quarter. Finally, Avanza Fonder AB lifted its stake in Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.